Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586772 | 0.82 | AHR (0.41) | AHRCYP19A1MAP2K1CNR1CA2 | |
| SCHEMBL5716711 | 0.74 | AHR (0.48) | AHRCYP19A1MAP2K1CNR1IDO1 | |
| SCHEMBL586564 | 0.71 | CYP19A1 (0.40) | CYP19A1MAP2K1CNR1CA2IDO1 | |
| Nicotinaldehyde SCHEMBL7150684 | 0.68 | PADI4 (0.41) | AHRCYP19A1MAP2K1CNR1IDO1 | |
| SCHEMBL399327 | 0.65 | AHR (0.50) | AHRCA2KDM4EHSD17B10HPGD | |
| SCHEMBL30435112 | 0.65 | AHR (0.50) | AHRCA2KDM4EHSD17B10HPGD | |
| SCHEMBL1685392 | 0.65 | AHR (0.50) | AHRCA2KDM4EHSD17B10HPGD | |
| SCHEMBL586565 | 0.65 | KDM4E (0.43) | CYP19A1MAP2K1CNR1CA2IDO1 | |
| SCHEMBL9959034 | 0.65 | CYP19A1 (0.45) | CYP19A1CA2CA12CA1CA9 | |
| SCHEMBL10325726 | 0.64 | CYP19A1 (0.41) | CYP19A1MAP2K1CNR1CA2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | AHR 474/4885CYP19A1 3368/4885MAP2K1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.